Oligonucleotide Drug Research


恒康LOGO-en

Oligonucleotide Drug Research

Hengkang Pharma provide 90% and 95% or customer purity for all below oligonucleotide, All oliconucleotide only for research and development.
Hengkang Pharma provide siRNA, ASO, etc custom synthesis service.

Synonym:GSK-3228836; IONIS-HBVRx; GSK836
Description:Beprovir is an antisense oligonucleotide developed by Ionis Pharmaceuticals Inc. It is a viral protein inhibitor. Currently, the highest development stage of the drug is Phase III clinical trial for the treatment of chronic hepatitis B.
Packing Size:100mg / 1g / 10g
Synonym:ISIS-301012; Kynamro; 米泊美生
Description:Mipomersen sodium is a first-in-class small molecule drug developed by Ionis Pharmaceuticals Inc. It is an APOB inhibitor. Currently, the highest development stage of this drug is withdrawal from the market, and it is used to treat type II hyperlipoproteinemia.
Packing Size:100mg / 1g / 10g
Synonym:ARO-LPA; AMG-890; ARC-LPA; RNAi ARC-LPA
Description:Olpasiran is a siRNA developed by Arrowhead Pharmaceuticals Inc and Amgen, and is an Lp(a) inhibitor. Currently, the highest development stage of the drug is Phase III clinical trial, which is used to treat atherosclerosis and atherosclerotic plaques.
Packing Size:100mg / 1g / 10g
Synonym:SYL-1001; SYL-1001-DP
Description:Tivanisiran is a siRNA developed by Sylentis Sa, a TRPV1 antagonist. Currently, the highest development stage of the drug is clinical phase III, which is used to treat Sjogren-Larsson syndrome and dry eye syndrome.
Packing Size:100mg / 1g / 10g
Synonym:ALN-60212; PCSK9si; ALN-PCSsc; KJX839; KJX-839; Leqvio; 乐可为; inclisiran; インクリシランナトリウム
Description:Inksilan sodium is a first-in-class siRNA developed by Alnylam Pharmaceuticals Inc. It is a PCSK9 inhibitor. Currently, the highest development stage of this drug is approval for marketing, which is used to treat hypercholesterolemia, dyslipidemia, carotid artery disease, heterozygous familial hypercholesterolemia and atherosclerosis.
On December 9, 2020, Inxlan sodium was approved by the European Medicines Agency (EMA) and is marketed by Novartis Europharm Ltd under the trade name Leqvio®. (EMEA/H/C/005333)
Packing Size:100mg / 1g / 10g
Synonym:ISIS-2922; Vitravene; Fomivirsenum; 福米韦生
Description:Fomivirsen sodium is an antisense oligonucleotide and a protein biosynthesis inhibitor. Currently, the highest development stage of this drug is withdrawal from the market, and it is used to treat cytomegalovirus retinitis.
Packing Size:100mg / 1g / 10g
Synonym:SPC-3549; SPC-3649; Miravirsen sodium; Liver-specific microRNA-122 antagonist – Roche; LNA-based miR-122 antagonis; miR-122 antagonist – Roche
Description:Miravirsen is an antisense oligonucleotide developed by Roche, which is a hepatitis C virus replication inhibitor and MIRN122 microRNA inhibitor. Currently, the highest development stage of this drug is no progress and it is used to treat chronic hepatitis C and hepatitis C.
Packing Size:100mg / 1g / 10g
Synonym:Synthetic miR-29 Mimic; promiR-29; MRG-201; MiR29 replacement; Synthetic microRNA-29 Mimic; Synthetic microRNA29 Mimic; promiR29
Description:Remlarsen is a microRNA developed by The University Of Texas Southwestern Medical Center and is a collagen inhibitor. Currently, the highest stage of development of this drug is clinical phase II for the treatment of keloids.
Packing Size:100mg / 1g / 10g
Synonym:99mTc-MAG3-BIIB067; ISIS-333611; BIIB-067; SODr/h333611; ISIS-SOD1Rx; IONIS SOD1Rx; QALSODY; Qalsody; 凯盛迪
Description:Tofusen is a first-in-class antisense oligonucleotide developed by Ionis Pharmaceuticals Inc and the Ludwig Institute for Cancer Research. It is a SOD inhibitor. Currently, the highest development stage of this drug is approval for marketing for the treatment of amyotrophic lateral sclerosis.
Packing Size:100mg / 1g / 10g

More Information

(0086)-576-93233919
bd1@hengkangpharm.cn
Scroll to Top